1910 AI Biotechnology

1910 AI Biotechnology

1910 AI Biotechnology is an AI-native biotech company that accelerates the discovery and optimization of small-molecule and large-molecule drugs by integrating artificial intelligence with automated laboratory technologies.
Rating:
5
Visit Website
AI drug discoveryAI biotech platformprotein structure predictionautomated drug developmentITO platformAI-driven drug design

Features of 1910 AI Biotechnology

Provide the ITO™ AI-powered platform that integrates multimodal data with automated laboratory capabilities
Supports end-to-end design, testing, and optimization of both small-molecule and large-molecule drugs
Generates novel compounds via deep learning to enable de novo drug design
Offers protein structure prediction functionality applied to drug design and enzyme engineering
Includes target discovery and validation capabilities, enabling virtual screening across numerous protein targets

Use Cases of 1910 AI Biotechnology

Pharmaceutical companies conducting new drug development use it for target identification and lead compound discovery
Researchers lacking a defined crystal structure use it to predict protein 3D structures to aid design
Biotech companies optimizing lead compounds use it for molecular generation and ADMET property prediction
When pharma companies need to shorten development timelines and reduce costs, adopt AI-driven end-to-end drug discovery workflows
Design novel therapeutic molecules for traditionally difficult targets (e.g., bispecific antibodies)

FAQ about 1910 AI Biotechnology

QWhat is 1910 AI Biotechnology?

1910 AI Biotechnology (1910 Genetics) is a biotech company focused on leveraging artificial intelligence and automation to accelerate drug discovery, with its core being the ITO™ AI-powered platform.

QWhat are the main capabilities of the 1910 AI Biotechnology platform?

The platform mainly supports end-to-end drug discovery from target identification to lead compound optimization, covering design, virtual screening, and optimization for both small molecules and large molecules (such as antibodies).

QWhat collaboration modes does the ITO platform offer?

Three main collaboration models: embedding ITO infrastructure, joint engineering development, and joint discovery collaborations from design to candidate drug delivery.

QWhat value does using the 1910 AI Biotechnology platform bring?

The core value lies in significantly shortening the drug development cycle, reducing R&D costs, and increasing success rates for hard-to-drug targets.

QWhich therapeutic areas does 1910 AI Biotechnology focus on?

The pipeline focuses on three main therapeutic areas: precision oncology, immunology and inflammation, and precision neuroscience.

QWhat is the data and algorithm foundation of the 1910 AI Biotechnology platform?

The platform is trained on large-scale biochemical databases (such as ChEMBL and ZINC) and integrates multimodal data with state-of-the-art AI models to improve predictive and generative accuracy.